BridgeMD
Compares treatment options for Asthma Exacerbations
Official title Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)
ClinicalTrials.gov ID: NCT07486401
What this study is testing
- What it's testing
- The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting. The study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better symptom control and improvement in quality of life compared to usual arm in mild to moderate asthma patients in the primary care setting.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 21 to 65
You may be able to join if
- Singaporeans or Singapore Permanent Residents
- Patients aged ≥21 to 65 years old
- Physician diagnosed asthma for duration of at least 4 weeks
- On or will be initiated on Global Initiative for Asthma (GINA) 2025 step 1-3) treatment
- No asthma exacerbations\ in the preceding 4 weeks before randomisation
You likely can't join if
- History of life-threatening asthma requiring intubation or intensive care unit admission
- Severe asthma or difficult to treat asthma
- Current use of long-term immunosuppression, LTRA receptor antagonist (Montelukast) and Theophylline or long-term oral steroids
- Presence of other known causes of eosinophilia besides asthma (e.g. parasitic infection), based on physician's discretion and investigation as per...
- Current use of beta-blocking agents including eye-drops
- Use of oral, rectal, or parenteral glucocorticoid within 30 days and/or depot parenteral glucocorticoid within 12 weeks prior to recruitment
See the full eligibility criteria
- Singaporeans or Singapore Permanent Residents
- Patients aged ≥21 to 65 years old
- Physician diagnosed asthma for duration of at least 4 weeks
- On or will be initiated on Global Initiative for Asthma (GINA) 2025 step 1-3) treatment
- No asthma exacerbations\ in the preceding 4 weeks before randomisation
- Able and willing to attend study appointments approximately every 4-monthly over a 1-year period
- Able to provide informed consent
- Stable cardiovascular status (i.e. controlled hypertension, no active symptoms of heart disease or arrhythmias) \ Exacerbations are defined as worsening of asthma symptoms requiring systemic corticosteroid for 3 or more...
- History of life-threatening asthma requiring intubation or intensive care unit admission
- Severe asthma or difficult to treat asthma
- Current use of long-term immunosuppression, LTRA receptor antagonist (Montelukast) and Theophylline or long-term oral steroids
- Presence of other known causes of eosinophilia besides asthma (e.g. parasitic infection), based on physician's discretion and investigation as per clinical practice and suspicion
- Current use of beta-blocking agents including eye-drops
- Use of oral, rectal, or parenteral glucocorticoid within 30 days and/or depot parenteral glucocorticoid within 12 weeks prior to recruitment
- Known diagnosis of Chronic Obstructive Pulmonary Disease, Interstitial lung disease or bronchiectasis
- Any significant disease or disorder (eg. Cardiovascular, pulmonary other than asthma, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical...
- Current enrolment in other treatment clinical trial for asthma
- Female people who are pregnant or planning pregnancy during the study period
- Planned travel outside of the country for ≥16 consecutive weeks during the study
- Investigator's assessment of poor capability of following study instructions or comply with study procedures
The study team makes the final eligibility decision.
Where it's taking place
- Singapore, Singapore
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 21 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Singapore, Singapore. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.